Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pfeffer, M.A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pfeffer, M.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


The intersection between acute coronary syndrome and heart failure

M.A. Pfeffer*

Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, U.S.A.

* Marc A. Pfeffer, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, U.S.A.

Abstract

There is a tremendous spectrum of disease severity within the diagnosis of myocardial infarction. The risk of major cardiovascular outcomes is highly related to age and concomitant medical conditions, as well as factors that characterize the extent of the myocardial infarction. Patients that develop pulmonary congestion with transient signs of heart failure and/or left ventricular dysfunction as measured by a reduced ejection fraction are generally at the high end of risk stratification. Prior studies have demonstrated that these patients derive particular benefit with the use of angiotensin-converting enzyme (ACE) inhibitors. The development of angiotensin-receptor blockers (ARBs) raises the question of whether this mode of inhibiting the renin-angiotensin system will be as good as or potentially even better than the ACE inhibitors. Unfortunately, the first major test of this concept in the Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL) study did not show a favourable trend for the ARB. The Valsartan in Acute Myocardial Infarction Trial (VALIANT) study is in its final phases of completion and is testing whether the use of the ARB valsartan either alone or in combination with captopril can improve survival over and above what is already achievable with the ARB. Since this patient population is at particularly high risk, even small relative improvements in clinical outcomes will have major public health implications.

Key Words: ACE inhibitor • angiotensin-receptor • blocker • heart failure • myocardial infarction • OPTIMAAL • VALIANT

References

  1. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341:625–634[Abstract/Free Full Text]
  2. Peel AAF, Semple T, Wang I. A coronary prognostic index for grading the severity of infarction. Br Heart J. 1962;24:745–760
  3. Norris RM, Caughey DE, Mercer CJ, et al. Coronary prognostic index for predicting survival after recovery from acute myocardial infarction. Lancet. 1970;2:485–487[Web of Science][Medline]
  4. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two-year experience with 250 patients. Am J Cardiol. 1967;20:457–464[CrossRef][Web of Science][Medline]
  5. Forrester JS, Diamond G, Chatterjee K, Swan HJ. Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med. 1976;295:1404–1413[Web of Science][Medline]
  6. Hellermann JP, Jacobsen SJ, Gersh BJ, Rodeheffer RJ, Reeder GS, Roger VL. Heart failure after myocardial infarction: a review. Am J Med. 2002;113:324–330[CrossRef][Web of Science][Medline]
  7. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. Circulation. 1995;91:1659–1668[Abstract/Free Full Text]
  8. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031–2037[Abstract/Free Full Text]
  9. Jacobs DR Jr., Kroenke C, Crow R, et al. PREDICT: a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. Circulation. 1999;100:599–607[Abstract/Free Full Text]
  10. Krumholz HM, Chen J, Chen YT, Wang Y, Radford MJ. Predicting one-year mortality among elderly survivors of hospitalization for an acute myocardial infarction: results from the Cooperative Cardiovascular Project. J Am Coll Cardiol. 2001;38:453–459[Abstract/Free Full Text]
  11. Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation. 2002;105:2605–2610[Abstract/Free Full Text]
  12. Steg PG, Dabbous O, Cohen-Solal A, et al. Determinants and outcomes of congestive heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events. [abstract]J Am Coll Cardiol. 2002;39:154a
  13. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE-inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 1998;97:2202–2212[Abstract/Free Full Text]
  14. Flather MD, Yusuf S, Kober L, et alACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575–1581[CrossRef][Web of Science][Medline]
  15. Pfeffer MA. ACE inhibitors in acute myocardial infarction. Patient selection and timing. [editorial]Circulation. 1998;97:2192–2194[Free Full Text]
  16. Solomon SD, Pfeffer MA. ACE inhibition following myocardial infarction: from left ventricular remodeling to improved survival. Gersh BJ, Rahimtoola SH. Acute Myocardial Infarction. 2nd edition. New York: Chapman & Hall; 1996. p. 704–716
  17. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801–807[Abstract]
  18. Hjalmarson A, Herlitz J, Malek I, et al. Effect on mortality of metroprlol in acute myocardial infarction: a double-blind randomized trial. Lancet. 1981;2:823–827[CrossRef][Web of Science][Medline]
  19. Beta Blocker Heart Attack Study Group. A randomized trial of propranolol in patients with acute myocardial infarction: mortality results. JAMA. 1982;247:1707–1714[Abstract/Free Full Text]
  20. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503–510[Abstract/Free Full Text]
  21. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9–13[CrossRef][Web of Science][Medline]
  22. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;333:2001–2007
  23. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390[CrossRef][Web of Science][Medline]
  24. Timmermans PB, Carini DJ, Chiu AT, et al. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens. 1991;4:275S–281S[Medline]
  25. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883–890[Abstract/Free Full Text]
  26. de Gasparo M, Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol. 1998;82:257–271[Web of Science][Medline]
  27. Goodfriend TL, Elliot ME, Catt JJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334:1649–1654[Free Full Text]
  28. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003[CrossRef][Web of Science][Medline]
  29. Skali H, Pfeffer MA. Prospects for ARB in the next five years. J Renin Angiotensin Aldosterone Syst. 2001;2:215–218[Free Full Text]
  30. Dickstein K, Kjekshus JOPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752–760[CrossRef][Web of Science][Medline]
  31. Dickstein K, Kjeshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Am J Cardiol. 1999;83:477–481[CrossRef][Web of Science][Medline]
  32. Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in Acute Myocardial Infarction Trial (VALIANT): rationale and design. Am Heart J. 2000;140:727–734[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pfeffer, M.A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pfeffer, M.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?